Source: Annual Congress 2013 –Treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Djukanovic, S. Wilson, M. Castro, R. Leigh, E. R. Sutherland, J. Canvin, G. Peachey, J. Ackrill, P. Georgiou, C. W. Chen (Southampton, Horsham, United Kingdom; St Louis, Denver, East Hanover, United States Of America; Calgary, Canada). Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial. Eur Respir J 2013; 42: Suppl. 57, 3540

Member's Comments

No comment yet.

Related content which might interest you: First clinical trial of a new IgE-adsorber in allergic asthma Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma Year: 2015 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Lung function response to omalizumab in severe allergic asthma patients in UK clinical practice: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 LATE-BREAKING ABSTRACT: A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Subcutaneous allergen specific immunotherapy and immunological response in patients with bronchial asthma and allergic rhinitis in India Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study Source: International Congress 2015 – Asthma mechanisms and management Year: 2015 Study on sputum differential counts in asthmatics controlled & uncontrolled on inhaled corticosteroids Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Patients with allergic and eosinophilic asthma in the German severe asthma registry Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Pharmacological effect of lysozyme for COPD and bronchial asthma with sputum: A randomized, placebo-controlled, cross-over study Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 A randomized, placebo-controlled trial using anti-IgE to treat allergic bronchopulmonary aspergillosis Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016